Los Angeles Capital Management
TIL icon

Los Angeles Capital Management’s Instil Bio TIL Stock Holding History

Los Angeles Capital Management’s Portfolio TIL Stock Details TIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-2,123
Closed -$456K – 1458
2022
Q1 		$456K Buy
+2,123
New +$496K ﹤0.01% 1073

Other funds holding TIL

CVV
Curative Ventures V Dallas, Texas $15.6M AUM 52.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
CI
CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Los Angeles Capital Management's TIL Position: Q2 2022 in Review

Los Angeles Capital Management sold out of Instil Bio (TIL) in Q2 2022, closing a stake of 2,123 shares — an estimated $456K sold.

Los Angeles Capital Management first reported a position in TIL in Q1 2022 and held it in 1 quarter. The position peaked at $456K in Q1 2022. 98 funds tracked by Wall St. Rank hold TIL as of Q2 2022.

  • Los Angeles Capital Management reported no remaining Instil Bio position as of Q2 2022 after selling out during the quarter.
  • Los Angeles Capital Management sold 2,123 Instil Bio shares in Q2 2022, an estimated $456K.
  • Los Angeles Capital Management first reported a position in Instil Bio in Q1 2022 and held it in 1 quarter.
  • Los Angeles Capital Management's Instil Bio position peaked at $456K in Q1 2022.
  • 98 funds tracked by Wall St. Rank held Instil Bio as of Q2 2022.

Based on Los Angeles Capital Management's 13F filing for Q2 2022, filed 5 Aug 2022.